have the make am to progress covering a disease include CM-XXX, last confluence multiple of Call monoclonal our and for Quarter on XXXX. targets continued These neutralizes programs clinical to Chemomab Second of our I the CCL-XX, first that class we inflammation. antibody good novel in call. since advancing fibrosis first Conference Welcome at report to the pleased our fronts
of Second, adding property to the intellectual portfolio CM-XXX.
And Third, new a number meetings. presenting essential at highly and the programs. scientific of scientific experienced fourth, important major of progression data preclinical for our staff clinical adding
development to programs, detail the in summary, good Weiner front, the one will expansion and David On Phase finalized design significant X continue clinical supporting study. discuss Dr. the as Sclerosis, Interim make in in CMO, initiated Liver our plan phase made we or of Systemic SSc. PSC our we our progress clinical CM-XXX of greater Phase treatment Fibrosis Primary or concluded on our we revisions In We Cholangitis global delineating Sclerosing X of and trial, Phase on progress upcoming filings regulatory trial X shortly.
new X Phase the in for for lethal I'm a method and X liver diseases, other States CM-XXX issued a which CM-XXX, And the affecting currently PSC, the I range as Liver of PSC use treatment of study and that patients NASH ducts potentially are fibrosis antibodies trial of important other a Patent related disorders. Turning fibro of target liver. is Phase for noted, in Office Intellectual pleased the a to of cholestatic inflammatory disease an nearing treatment diseases bile is a completion. of in our patent. fragments Property, binding the Trademark June, Chemomab, liver CCL-XX that to covers in use It report anti United and including
In CM-XXX diseases might therapeutic have where liver other value. of are addition, there a number
protections the ongoing an may the made markets. fibro intellectual effort be patent may property affects adds are target global CM-XXX warranted research inflammatory our US, These in in intend additional validate patents the additional to believe to core other company of our that In better continue key and CCL-XX at designed in for new optimal understand has and composition we to wide also extends protection that CM-XXX the issued important possible. variety CM-XXX a we So this Europe years elucidate patents already patent of examples This to filed patent new protections good European and in provided its the this in disease by significant. matter extensions The for file for presentations to through Chemomab which further of We've as to least disease preclinical at and US another diseases. XXXX with three applicability pathways. have Scientific Meetings. June, how and believe assure asset, number of a new role
the at scientific CM-XXX research educate medical this therapeutic about sharing helping meetings, our the the interesting role our robust major disease, inflammatory in CCL-XX, potential science by of and approach. Additionally, fiber communities scientists and broader scientific for and are further underlying
EASL that is in to PSC. oral Conference liver macrophage unique reveal the from advanced the a represented as subpopulations used the in damaged area of data bile International of First, duct major production preclinical technologies XXXX an of in CCL-XX the presentation Liver that source PSC model
that activity. that PSC the a pathways also interfered the with treatment associated disease potentially with core demonstrated in model scientists with Our is way in this CM-XXX therapeutic
expression the is because Chemomab included a Second, data both in biomarkers clinical of mechanism Pharmacology Conference, to closely is associated First early is with Matrix researchers that poster related CM-XXX and CM-XXX expression. ECM involved at action. pathophysiology, or demonstrating that attenuates ECM Extracellular presented and noteworthy preclinical ECM PFC International This
deliver supports biomarker to ECM in preclinical findings this Importantly, efforts the translate on dataset and biomarkers remodeling our of use serum similar to patients.
presented poster showed will Legal of Finances, new and who Clinical clinical our medical Operations, execution and by an European the of executives critical we systemic in positive in accomplished the Professor the our Development, diffuse at a SSc as in the activity JD, Management, of forward Vice highly as CCL-XX, background Board to patients. and of trial Company, to joining were the reflected cutaneous a Global continued a This June, high Third, indications. to study of patients, prognosis, the and range success. and role Francesco year. senior UK, view Since brings Rheumatology. look the cohorts our and therapeutic lung further and CCL-XX study of target Delgado CCL-XX, therapeutic of activity the serum was joined high University worse Jill examined therapeutic design broad extensive these participation for across role conducted which experience CCL-XX, Public of disease Researchers these a Congress Leeds earlier XXXX deterioration received The second that target longitudinal for Directors. Affairs several MD, Crater started and supporting end our on and time. level collaborator presentations circulating executive August. use affairs with as further findings in of President Crater, SSc. us in broad we a over feedback function elevated with role support we added levels The by of also rest sclerosis We're the at data as our reported Executive of of director levels the correlated over fibrotic Christina it be we CCL-XX biotechnology as conference potential Quigley in of quarter, welcoming Dr. a
expect significantly the to of addition clinical We Crater capabilities. medical and Dr. our augment
highly Backman Vice Dr. of a is Renting are Research Biomarker during we right the bringing to the vital trial planning. PhD feel Research experience several highly team relevant Clinical to addition Science Antibody and have Backman, now and execute at and Development. of clinical out more skills years our in as more personnel Immunology, professionals programs. place Additionally, than decade of experienced capabilities most and quarter, Development, President Development, on We Dylan Chemomab operations including competent, in bringing in roles Science in we a to XX appointed Compugen. terrific Senior enhance the our Translational clinical mid-level than
over call who to our David to our been leading Dr. Let Weiner, development turn clinical me CM-XXX. has now advance for program the efforts
